A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours
Stopped This study was terminated early as per protocol Section 4.4, based on overall risk-benefit profile observed to date. No safety concerns reported. Only Substudy 1 Part A was started; Parts B \& C were not started. Entire Master Protocol was terminated.
Conditions
- Urinary Bladder Neoplasms
- Colorectal Cancer
- Carcinoma, Non-Small-Cell Lung
Interventions
- DRUG: AZD8853
- DRUG: Zirconium-89 crefmirlimab berdoxam
Sponsor
AstraZeneca
Collaborators